Tor is particularly interested in the combination of clinical data, biochemical analyzes and artificial intelligence to unleash the potential of research and innovational projects.
Tor is an ophthalmologist with a special interest in the combination of clinical data, biochemical analyzes and artificial intelligence to unleash the potential of research and innovational projects. Thus, in the long run, to be able to contribute to better diagnostics and treatment.
In recent years, he has had a particular focus on networking between different environments as he believes it will be both innovation and research that forms the future. This vision has resulted in him now sharing much of his time between six universities and five hospitals.
Tor has given a number of lectures on dry-eyes, stem cells and innovation internationally, including the Royal Society of Medicine in London, Harvard Medical School and the American Academy of Arts and Science in Cambridge, Massachusetts.
He has been a key speaker at OsloMet, the Iranian Ophthalmological Association and the Specsavers Clinical Conference in Norway, Denmark, Sweden, Finland, and the Netherlands.Tor has contributed to Novartis Global Advisory Board, Alcon Global Advisory Board and Shire European Advisory Board. Furthermore, he has contributed to seven business start-ups, one of which has external funding solely based on two of his patent applications.